#South Korea #Seoul #Grants #Seegene #Nature Awards

Seegene and Springer Nature's Partnership for Innovation in Diagnostics

On September 2, 2025, Seegene Inc., a global leader in molecular diagnostics, announced the opening of applications for the 2025-2026 Nature Awards MDx Impact Grants in collaboration with Springer Nature. This initiative targets one of the most significant challenges in public health today: antibiotic resistance in urinary tract infections (UTI-DR). Researchers worldwide can contribute their innovative solutions to tackle this pressing issue before applications close on November 20, 2025.

The program invites researchers to submit ideas for product development and clinical research projects focusing on up to 18 resistance genes linked to urinary tract infections. Awardees, selected based on the impact and feasibility of their proposals, will have the opportunity to receive grants up to USD 600,000. Moreover, they will gain access to Seegene's advanced syndromic PCR assays, instruments, and software, essential tools that can significantly elevate the development of novel diagnostics.

Richard Hughes, Vice President Publishing at Springer Nature, commented on the significance of this partnership, highlighting their commitment to enhancing platforms for scientists and fostering innovation in research. He stated, "Through this program, we aim to help researchers develop diagnostic solutions that can make a difference in healthcare worldwide."

Seegene's Dr. Jik Young Park emphasized their crucial role in providing the necessary tools and technologies, aiding scientists in translating innovative ideas into effective solutions. This collaboration aims to catalyze global research efforts by offering both funding and access to essential PCR technologies. This initiative is aligned with Seegene's vision of creating a world free from all diseases through consistent advancements in molecular diagnostics.

The Nature Awards MDx Impact Grants represent a vital effort not only to fund specific projects but also to complement ongoing global initiatives in diagnostics. During the previous cycle, initiatives were launched focusing on rapid detection methods for ViruResist Klebsiella pneumoniae and multiplex PCR assays for viral detection among immunocompromised patients. This cycle's emphasis on UTI-DR reflects the critical necessity for rapid and effective diagnostic tools in the face of escalating antibiotic resistance.

Seegene has over 20 years of experience in the molecular diagnostics field, showcasing its ability to transform scientific innovations into practical methods that benefit global health. The company made headlines during the COVID-19 pandemic by providing more than 340 million tests to countries worldwide, a testament to its expansive reach and commitment to public health.

Seegene's proprietary syndromic quantitative PCR technology sets it apart, allowing for simultaneous detection of multiple pathogens causing similar symptoms in just one test. This multi-tube panel testing expands coverage to include dozens of clinically relevant pathogens, facilitating better management of co-infections.

Through the integration of its technology-sharing initiative, Seegene aims to co-develop tailored diagnostic products alongside leading experts and institutions globally. By ensuring scientists can collaborate efficiently, they are one step closer to realizing their goal of eradicating diseases.

The announcement is expected to spark a surge of innovative proposals and foster a collaborative spirit among the scientific community. Interested researchers are encouraged to take advantage of this opportunity to contribute to vital advancements in healthcare.

About Seegene

Seegene Inc. continues to lead in the realm of molecular diagnostics, with a commitment to sustaining advancements in technology and research. For more information, please visit Seegene.com and follow them on LinkedIn.

About Nature Portfolio

Nature Portfolio celebrates scientific excellence with a broad array of publications dedicated to global research across various fields. Nature is recognized as a premier journal that features groundbreaking discoveries and innovations.